Haloperidol versus risperidone for schizophrenia
Referencias
Additional references
Adams CE, Bergman H, Irving CB, Lawrie S. Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD003082.pub3]
Addington DE, Jones B, Bloom D. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clinical Therapeutics 1993;15:917‐26.
Altman DG, Bland JM. Detecing skewness from summary information. BMJ 1996;313:1200. [RSPT020600]
Andreasen NC. Negative syndrome in schizophrenia: strategies for long‐term management. Advances in Biochemical Psychopharmacology 1985;40:1‐7.
Bhattacharjee J, El‐Sayeh HG. Aripiprazole versus haloperidol for people with schizophrenia and schizophrenia‐like psychoses. Cochrane Database of Systematic Reviews 2016, Issue 2. [DOI: 10.1002/14651858.CD012073]
Bhugra D. The global prevalence of schizophrenia. PLoS Medicine 2005;2(5):e151.
Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405‐11. [PUBMED: 10667106]
Chouinard G, Arnott W. Clinical review of risperidone. Canadian Journal of Psychiatry 1993;38(suppl 3):89‐95.
Christison GW, Kirch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic symptoms for schizophrenia. Schizophrenia Bulletin 1991;17:217‐45.
Christodoulou C, Kalaitzi C. Antipsychotic drug‐induced acute laryngeal dystonia: two case reports and a mini review. Journal of Psychopharmacology 2005;19(3):307‐11.
Crow TJ. Positve and negative schizophrenic symptoms and the role of dopamine. British Journal of Psychiatry 1980;137:383‐6.
Curtis V, Kerwin R. A risk benefit assessment of risperidone in schizophrenia. Drug Safety 1995;12:139‐45.
Davis JM, Casper R. Antipsycotic drugs: clinical pharmacology and therapeutic use. Drugs 1977;14:260‐82.
Deeks J. Issues in the selection for meta‐analyses of binary data. 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. The Cochrane Collaboration, 2000.
Deeks JJ, Higgins JPT, Altman DG, editor(s). Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623‐9.
Dold M, Leucht S. Pharmacotherapy of treatment‐resistant schizophrenia: a clinical perspective. Evidence Based Mental Health 2014;17:33‐7.
Donner A, Klar N. Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine 2002;21(19):2971‐80.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. American Psychiatric Association, 2013.
Egger M, Davey‐Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315:629‐34.
Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9.
Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7‐10.
Greenbaum L, Smith RC, Lorberboym M, Alkelai A, Zozulinsky P, Lifschytz T, et al. Association of the ZFPM2 gene with antipsychotic‐induced parkinsonism in schizophrenia patients. Psychopharmacology 2012;220(3):519‐28.
Guest JF, Hart WM, Cookson RF, Lindstrom E. Pharmocoeconomic evaluation of long‐term treatment with risperidone for patients with chronic schizophrenia. British Journal of Medical Economics 1996;10:59‐67.
Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876‐83.
Gupta S, Black D, Smith D. Risperidone: review of its pharmacology and therapeutic use in schizophrenia. Annals of Clinical Psychiatry 1994;6:173‐80.
Hasan A, Falkai P, Wobrock T, Lieberman J, Genthoj B, Gattaz WF, et al. The WFSBP Task Force On Treatment Guidelines For Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World Journal of Biological Psychiatry 2012;13:318‐78.
He H, Richardson JS. A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5‐HT2 and dopamine D2 receptors. International Clinical Psychopharmacology 1995;10:19‐30.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60.
Higgins JPT, Green S, editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Higgins JPT, Altman DG, Sterne JAC, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Hunter R, Kennedy E, Song F, Gadon L, Irving CB. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI: 10.1002/14651858.CD000440]
Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27‐30.
World Health Organization. The ICD‐10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization, 1992.
Irwig L, Macaskill P, Berry G, Glasziou P. Bias in meta‐analysis detected by a simple, graphical test. Graphical test is itself biased. BMJ 1998;316:470. [MEDLINE: 9492687]
Joy CB, Adams CE, Lawrie SM. Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2001, Issue 2. [DOI: 10.1002/14651858.CD003082.pub3]
Kane JM. Treatment programme and long term outcome in chronic schizophrenia. Acta Psychiatrica Scandinavica 1990;358:151‐7.
Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986.
Keltner Nl. Risperidone: the search for a better antipsychotic. Perspectives in Psychiatric Care 1995;31:30‐3.
Laursen TM, Munk‐Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Current Opinion in Psychiatry 2012;25(2):83‐8.
Leon AC, Mallinckrodt CH, Chuang‐Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry 2006;59(11):1001‐5.
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2‐3):231‐8.
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366‐71. [PUBMED: 16199797]
Leucht C, Kitzmantel M, Kane J, Leucht S, Chua WLLC. Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD004278.pub2]
Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple‐treatments meta‐analysis. Lancet 2013;382:951‐62.
Llorca PM, Miadi‐Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, et al. Cost‐effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long‐acting injection formulation [Analyse coût‐efficacité des stratégies de prise en charge des patients schizophrènes : place d’un antipsychotique atypique sous forme injectable à libération prolongée]. L'Encéphale 2005;31:235‐46.
López‐Muñoz F, Alamo C, Cuenca E, Shen WW, Clervoy P, Rubio G. History of the discovery and clinical introduction of chlorpromazine. Annals of Clinical Psychiatry 2005;17(3):113‐35.
Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249‐52.
Marwaha S, Johnson S. Schizophrenia and employment ‐ a review. Social Psychiatry and Psychiatric Epidemiology 2004;39(5):337‐49.
Meltzer HY, Lee MA, Ranjan R. Recent advances in the pharmacotherapy of schizophrenia. Acta Psychiatrica Scandinavica 1994;90:s95‐101.
MIMS. http://www.medeconomics.co.uk/.
Mirabzadeh A, Kimiaghalam P, Fadai F, Samiei M, Daneshmand R. The therapeutic effectiveness of risperidone on negative symptoms of schizophrenia in comparison with haloperidol: a randomized clinical trial. Basic Clinical Neuroscience 2014;5(3):212‐7.
Nandra KS, Agius M. The differences between typical and atypical antipsychotics: the effects on neurogenesis. Psychiatria Danubina 2012;24(Suppl 1):S95‐9.
Olfson M, Gerhard T, Huang C, Crystal S, Stroup TS. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 2015;72(12):1172‐81.
Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799‐812.
Ramachandraiah CT, Subramaniam N, Tancer M. The story of antipsychotics: past and present. Indian Journal of Psychiatry 2009;51(4):324–6.
Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto mental and addictive disorders service system. Epidemiologic Catchment Area prospective 1‐year prevalence rates of disorders and services. Archives of General Psychiatry 1993;50(2):85–94.
Remington GJ. Clinical considerations in the use of risperidone. Canadian Journal of Psychiatry 1993;38:96‐100.
Sadock BJ, Sadock VA, Ruiz P. Kaplan and Sadock's Comprehensive Textbook of Psychiatry. 9th Edition. Philadelphia: Lippincott Williams and Wilkins, 2009.
Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Scottish Drug Tariff. http://www.isdscotland.org/Health‐Topics/Prescribing‐and‐Medicines/Scottish‐Drug‐Tariff/.
Seeman P. Atypical antipsychotics: mechanism of action. Canadian Journal of Psychiatry 2002;47(1):27‐38.
Shen WW. A history of antipsychotic drug development. Journal of Comprehensive Psychiatry 1999;40(6):407‐14.
Sterne JAC, Egger M, Moher D, editor(s). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Stip E, Lussier I. The effect of risperidone on cognition in patients with schizophrenia. Canadian Journal of Psychiatry 1996;41:35‐40.
Swanson JW, Swartz MS, Elbogen EB. Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community‐based treatment. Schizophrenia Bulletin 2004;30(1):10‐2.
Tandon R. Antipsychotics in the treatment of schizophrenia: an overview. Journal of Clinical Psychiatry 2011;72(Suppl 1):4‐8. [DOI: 10.4088/JCP.10075su1.01.]
Tsuang MT. Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Archives of General Psychiatry 1978;35:153–5.
Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area‐wide and organistation‐based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1‐75.
World Health Organization. The World Health report 2001 ‐ Mental Health: New Understanding, New Hope. www.who.int/whr/2001/en/ (accessed 13 October 2016).
References to other published versions of this review
Ir a:
Song F. Risperidone in the treatment of schizophrenia: a metanalysis of randomized controlled trials. Journal of Psychopharmacology 1997;11:65‐71.
| Review Title | Stage | Reference | DOI |
| Aripiprazole versus haloperidol for people with schizophrenia and schizophrenia‐like psychoses | Protocol | ||
| Haloperidol versus chlorpromazine for schizophrenia | Full review | ||
| Haloperidol versus placebo for schizophrenia | Full review | ||
| Haloperidol versus risperidone for schizophrenia | ‐ | Current review |
Figuras y tablas -
Table 1. Haloperidol direct comparison reviews currently registered with Cochrane Schizophrenia
